Dana-Faber Cancer Institute

Boston, Massachusetts 02215

2 studies enrolling now · 20 studies all time

What they study most

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic Solid Tumors, B-Cell Malignancies, Breast Cancer, Castration Resistant Metastatic Prostate Cancer, Colorectal Cancer, Cowden Syndrome, Endometrial Cancer

Studies at this site

• Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression — Recruiting now
• A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors — Recruiting now
• A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors — Running, not enrolling
• Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype — Stopped early
• A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib — Completed
• Study to Assess AFM24 in Advanced Solid Cancers — Stopped early
• Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma — Completed
• An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia — Completed
• An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha — Completed
• Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients — Completed
• PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia — Completed
• A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer — Completed
• A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma — Stopped early
• Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma — Completed
• Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index — Completed
• Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML — Completed
• Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma — Completed
• Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Completed
• Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML — Completed
• Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors — Completed